Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 811-819 , October 2009

In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy

  • Bart Cornelissen

      Affiliations

    • Division of Nuclear Medicine, University Health Network, Toronto, ON, Canada M5S 3E2
    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • MRC/CRUK Gray Institute for Radiation Oncology and Biology, Oxford University, OX3 7LJ Oxford, UK
    • Corresponding Author InformationCorresponding author. Gray Institute for Radiation Oncology and Biology, Radiobiology Research Institute, Churchill Hospital, Headington, OX3 7LJ Oxford, UK.
    • ,
  • Veerle Kersemans

      Affiliations

    • Division of Nuclear Medicine, University Health Network, Toronto, ON, Canada M5S 3E2
    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Kristin McLarty

      Affiliations

    • Division of Nuclear Medicine, University Health Network, Toronto, ON, Canada M5S 3E2
    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Lara Tran

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Katherine A. Vallis

      Affiliations

    • MRC/CRUK Gray Institute for Radiation Oncology and Biology, Oxford University, OX3 7LJ Oxford, UK
    • ,
  • Raymond M. Reilly

      Affiliations

    • Division of Nuclear Medicine, University Health Network, Toronto, ON, Canada M5S 3E2
    • Department of Medical Imaging, University of Toronto, Toronto, ON, Canada M5S 3E2
    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2

Received 26 January 2009 ,Revised 28 April 2009 ,Accepted 10 May 2009.

References 

  1. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89:4285–4289
  2. Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt) 2002;16:1340-8, 51-2. [discussion 52, 55-8].
  3. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002;29:231–245
  4. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res. 2003;9:5078–5084
  5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Sciences (New York). 1987;235:177–182
  6. Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?. Ann Oncol. 2003;14:1697–1704
  7. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19:6102–6114
  8. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–3038
  9. Albanell J, Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst. 2001;93:1830–1832
  10. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  11. Vogel CL, Franco SX. Clinical experience with trastuzumab (Herceptin). Breast J. 2003;9:452–462
  12. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 2000;20:3210–3223
  13. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res. 2000;6:260–270
  14. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62:4132–4141
  15. Marches R, Uhr JW. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer. 2004;112:492–501
  16. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64:3981–3986
  17. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev. 2008;8:253–267
  18. Jeon JH, Lee KN, Hwang CY, Kwon KS, You KH, Choi I. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res. 2005;65:4485–4489
  19. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm. 2008;23:3–24
  20. Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des. 2008;14:2415–2447
  21. Cornelissen B, Hu M, McLarty K, Costantini D, Reilly RM. Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol. 2007;34:37–46
  22. Cornelissen B, McLarty K, Kersemans V, Scollard DA, Reilly RM. Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nucl Med Biol. 2008;35:101–110
  23. Hu M, Chen P, Wang J, Chan C, Scollard DA, Reilly RM. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur J Nucl Med Mol Imaging. 2006;33:301–310
  24. Hu M, Chen P, Wang J, Scollard DA, Vallis KA, Reilly RM. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). Eur J Nucl Med Mol Imaging. 2007;34:368–377
  25. Hu M, Wang J, Chen P, Reilly RM. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Bioconjug Chem. 2006;17:1280–1287
  26. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80:849–857
  27. Reed W, Florems VA, Holm R, Hannisdal E, Nesland JM. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch. 1999;435:116–124
  28. Baekelandt M, Holm R, Trope CG, Nesland JM, Kristensen GB. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res. 1999;5:2848–2853
  29. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357–1368
  30. Macara IG. Transport into and out of the nucleus. Microbiol Mol Biol Rev. 2001;65:570–594table of contents
  31. Cornelissen B, Kersemans V, McLarty K, Tran L, Reilly RM. 111In-Labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cancer Biother Radiopharm. 2009;in press
  32. Crombez L, Morris MC, Deshayes S, Heitz F, Divita G. Peptide-based nanoparticle for ex vivo and in vivo drug delivery. Current Pharma Des. 2008;14:3656–3665
  33. Pujals S, Fernandez-Carneado J, Lopez-Iglesias C, Kogan MJ, Giralt E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim Biophys Acta. 2006;1758:264–279
  34. Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boye K, et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer. 2007;96:269–276
  35. Shrader M, Pino MS, McConkey D. ZD1839 (Iressa™) sensitivity is regulated through a p27-dependent mechanism in bladder cancer cells. In: AACR Meeting Abstracts. 2005;p. 802
  36. Shintani S, Li C, Mihara M, Yano J, Terakado N, Nakashiro K, et al. Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral oncology. 2004;40:43–51
  37. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol. 2006;155:371–379
  38. Moore HG, Shia J, Klimstra DS, Ruo L, Mazumdar M, Schwartz GK, et al. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol. 2004;11:955–961

☆ This study was supported by grants from the Ontario Cancer Research Network (No. 03-NOV-0428 and 1 mm Cancer Challenge) with funds from the Province of Ontario.

PII: S0969-8051(09)00127-9

doi: 10.1016/j.nucmedbio.2009.05.003

Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 811-819 , October 2009

Article Tools

* Image Usage & Resolution